Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197845 · ClinicalTrials.gov registry record · NA
Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 353
- Enrollment target
NCT02197845: Completed NA study, sponsored by Virginia Commonwealth University.
NCT02197845 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 353 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02197845, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 353 participants
- Enrollment target
Study Summary
Multi-phase, patient navigator-based program in the Richmond and Tidewater regions of Virginia to demonstrate: 1. the feasibility of using patient navigators to improve the percentage of children and adult (age 15 and older) patients with sickle cell disease (SCD) in SCD specialty care 2. the efficacy of using patient navigators to improve hydroxyurea (HU) (re-)initiation and adherence among adult patients with SCD eligible for HU (Patient navigators may also be known as public health workers.)
Interventions
- BEHAVIORAL Patient Navigator
- BEHAVIORAL Recruitment into Specialty Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2012-10 |
| Est. Completion | 2018-12-31 |
| Phase | NA |
What the finished NCT02197845 record still lists
NCT02197845 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Patient Navigator is the first listed.
NCT02197845 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02197845 about?
NCT02197845 is a clinical study titled "Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators". Multi-phase, patient navigator-based program in the Richmond and Tidewater regions of Virginia to demonstrate: 1. the feasibility of using patient navigators to improve the percentage of children and adult (age 15 and older) patients with sickle cell disease (SCD) in SCD specialty care 2. the effic...
What is the current status of trial NCT02197845?
This trial is currently completed. It is a NA study. The enrollment target is 353 participants. The study started on 2012-10. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT02197845?
The interventions under investigation include: Patient Navigator (BEHAVIORAL), Recruitment into Specialty Care (BEHAVIORAL).
Who is sponsoring clinical trial NCT02197845?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02197845's enrollment target sits among peer trials
353 292nd of 2000 higher than 1,709 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia